IMGN...certainly oversold
Current cap now $85m. Interesting despite recent news.
(I recommend this link for some relevant background to the whole MAB targeted approach, though:
"Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies"
medscape.com )
March 31, June 30,
2002 2001
ASSETS (Unaudited)
Cash and marketable securities $144,002 $150,800
Other assets 12,652 8,361
Total assets $156,654 $159,161
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities $6,998 $5,361
Long term portion of deferred
revenue and other long term
liabilities 11,828 11,353
Stockholders' equity 137,828 142,447 |
